简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:Lawmakers from Mexico's ruling party plan to send a bill to Congress that would set maximum drug prices, aiming to improve accessibility for poor patients and bring costs in line with cheaper countries in the region. <
MEXICO CITY (Reuters) - Lawmakers from Mexico's ruling party plan to send a bill to Congress that would set maximum drug prices, aiming to improve accessibility for poor patients and bring costs in line with cheaper countries in the region.
The proposal for new pharmaceutical regulations, which MORENA lawmakers announced on Sunday, says it seeks to ensure “affordable prices that are in touch with the economic reality” of Mexico. A source at the party said the bill will be introduced this week.
Pharmaceutical companies in the United States and Canada are similarly under pressure from lawmakers to control rising drug costs.
Mexican President Andres Manuel Lopez Obrador, who took office in December vowing to fight poverty and inequality, has urged pharmaceutical companies to lower their prices or risk losing out on government business to competitors.
His MORENA party has launched several initiatives to reduce costs for consumers, with mixed results. Proposed changes to Mexico's pension system were praised by ratings agency Fitch, and millions of poor families could benefit from a government push to cut fees on remittances.
However, a proposal to cut banking commissions concerned investors and triggered a stocks sell-off. Lopez Obrador later said he would not immediately change the banking laws.
The country's economy and health ministries would work together to set maximum prices once a year or as necessary, the proposal says, without providing further detail.
The proposal cites a study by Peruvian investigative journalism outlet Ojo Publico. The study says prices, adjusted for purchasing power, are much higher in Mexico than in other Latin American countries for certain drugs, including those that treat diabetes, cancer and HIV.
Mexico's national pharmaceutical association declined to comment.
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.